Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
IDEAYA Biosciences $350 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Alector $75 million stock offering
The common stock is listed on the Nasdaq Global Select Market
Sun Pharmaceutical enters into merger agreement with Taro Pharmaceutical
We are advising Sun Pharma on the transaction
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition
OPKO Health $230 million convertible senior notes offering
The 3.75% convertible notes are due 2029
Auna $550 million secured term loan refinancing
We advised Auna on the transaction
Solid Biosciences $109 million private placement
The PIPE includes common stock and pre-funded warrants
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Air Methods emerges from chapter 11
We advised the ad hoc group that negotiated and backstopped the restructuring
HighTide Therapeutics HK$194.1 million IPO
We advised HighTide Therapeutics on its IPO and HKEX listing